Profile data is unavailable for this security.
About the company
Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.
- Revenue in AUD (TTM)697.94k
- Net income in AUD-7.74m
- Incorporated1986
- Employees3.00
- LocationPrescient Therapeutics LtdL 4 100 Albert RdSOUTH MELBOURNE 3205AustraliaAUS
- Phone+61 39692-7222
- Fax+61 39077-9233
- Websitehttps://ptxtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAL Diagnostics Ltd | 3.67m | -5.00m | 23.97m | -- | -- | 3.94 | -- | 6.52 | -0.0227 | -0.0227 | 0.0166 | 0.0241 | 0.4493 | -- | 3.21 | -- | -61.10 | -54.01 | -67.83 | -62.57 | -- | -- | -136.00 | -248.64 | -- | -131.83 | 0.1985 | -- | 298.63 | 63.18 | -49.51 | -- | 91.62 | -- |
| Chimeric Therapeutics Ltd | 0.00 | -11.31m | 25.55m | -- | -- | 1.57 | -- | -- | -0.027 | -0.027 | 0.00 | 0.0191 | 0.00 | -- | -- | -- | -45.96 | -- | -69.36 | -- | -- | -- | -- | -- | -- | -10.01 | 0.1596 | -- | -- | -- | -60.40 | -- | -- | -- |
| Lumos Diagnostics Holdings Ltd | 12.60m | -13.53m | 26.47m | -- | -- | 1.87 | -- | 2.10 | -0.0364 | -0.0364 | 0.0358 | 0.0294 | 0.3418 | 2.24 | 6.37 | -- | -36.70 | -40.15 | -55.14 | -56.67 | 59.73 | 45.97 | -107.38 | -162.90 | 0.479 | -6.25 | 0.4803 | -- | -9.42 | 39.29 | 80.38 | -- | -38.50 | -- |
| LBT Innovations Limited | 2.00m | -21.38m | 26.79m | 17.00 | -- | 9.87 | -- | 13.37 | -0.0428 | -0.0428 | 0.0038 | 0.002 | 0.1087 | 0.0819 | 2.25 | 117,882.40 | -115.89 | -28.85 | -131.86 | -30.99 | 94.76 | -- | -1,066.62 | -441.76 | 3.30 | -6.85 | 0.5633 | -- | -5.29 | -18.45 | -239.17 | -- | -34.63 | -- |
| Cann Group Ltd | 16.45m | -29.28m | 27.12m | 40.00 | -- | 0.5339 | -- | 1.65 | -0.0724 | -0.0724 | 0.0406 | 0.1161 | 0.1237 | 0.3952 | 7.37 | -- | -22.03 | -22.28 | -34.23 | -24.43 | 21.11 | -- | -178.07 | -407.57 | 0.0861 | -5.88 | 0.5646 | -- | 114.90 | 89.76 | -27.66 | -- | -11.16 | -- |
| Alterity Therapeutics Ltd | 123.46k | -12.28m | 31.43m | 11.00 | -- | 0.9541 | -- | 254.56 | -0.005 | -0.005 | 0.00005 | 0.0063 | 0.0044 | -- | 1.52 | 11,223.64 | -44.20 | -53.02 | -53.57 | -61.96 | -- | -- | -9,947.97 | -40,995.62 | -- | -- | 0.0143 | -- | 557.60 | -39.40 | -7.47 | -- | -34.88 | -- |
| IDT Australia Limited | 10.36m | -6.55m | 33.39m | 156.00 | -- | 1.45 | -- | 3.22 | -0.022 | -0.022 | 0.035 | 0.0656 | 0.3741 | 2.39 | 3.51 | -- | -23.64 | -9.87 | -26.41 | -11.57 | 76.38 | 84.42 | -63.19 | -24.94 | 2.81 | -- | 0.0907 | -- | -42.03 | -11.97 | -632.59 | -- | -26.04 | -- |
| Little Green Pharma Ltd | 23.24m | -3.14m | 37.72m | -- | -- | 0.4649 | 56.45 | 1.62 | -0.011 | -0.0126 | 0.0833 | 0.2689 | 0.263 | 1.13 | 12.06 | -- | -3.55 | -- | -4.01 | -- | 51.02 | -- | -13.51 | -- | 2.03 | -21.27 | 0.0667 | -- | -- | -- | -- | -- | -- | -- |
| Cynata Therapeutics Ltd | 436.25k | -13.65m | 37.72m | 0.00 | -- | 3.07 | -- | 86.47 | -0.0873 | -0.0873 | 0.0027 | 0.0683 | 0.0257 | -- | 4.26 | -- | -80.33 | -38.07 | -87.15 | -41.10 | -- | -- | -3,127.93 | -513.73 | -- | -- | 0.00 | -- | -94.96 | 19.81 | -162.20 | -- | -- | -- |
| Invion Ltd | 4.46m | -1.50m | 38.55m | 8.00 | -- | 2.16 | -- | 8.64 | -0.0002 | -0.0002 | 0.0007 | 0.0028 | 0.2345 | -- | 3.20 | -- | -7.88 | -16.93 | -8.12 | -18.13 | -- | -- | -33.60 | -51.63 | -- | -- | 0.00 | -- | 25.72 | 41.18 | 27.95 | -- | -- | -- |
| Prescient Therapeutics Ltd | 697.94k | -7.74m | 41.88m | 3.00 | -- | 1.85 | -- | 60.00 | -0.0098 | -0.0098 | 0.0009 | 0.0281 | 0.0276 | -- | 2.32 | -- | -30.58 | -27.61 | -32.59 | -29.03 | -- | -- | -1,109.58 | -3,284.78 | -- | -412.91 | 0.00 | -- | 939.16 | 29.68 | -36.88 | -- | -- | -- |
| Inoviq Ltd | 751.54k | -6.51m | 48.31m | 85.00 | -- | 2.89 | -- | 64.28 | -0.0708 | -0.0708 | 0.0082 | 0.182 | 0.0339 | 2.10 | 0.873 | -- | -29.33 | -47.68 | -32.18 | -50.76 | 95.07 | -- | -866.27 | -2,527.82 | 4.93 | -- | 0.0332 | -- | 119.59 | 153.31 | 50.71 | -- | -- | -- |
| Biotron Ltd | 1.65m | -4.02m | 55.04m | 4.00 | -- | 29.44 | -- | 33.46 | -0.0045 | -0.0045 | 0.0018 | 0.0021 | 0.3587 | -- | -- | -- | -87.73 | -64.30 | -103.46 | -74.43 | -156.30 | -108.03 | -244.54 | -231.62 | -- | -- | 0.0148 | -- | -8.16 | -2.48 | -25.59 | -- | -- | -- |
| Anteotech Ltd | 526.75k | -11.46m | 55.39m | 40.00 | -- | 10.63 | -- | 105.16 | -0.0056 | -0.0056 | 0.0003 | 0.0022 | 0.0552 | -- | 2.62 | -- | -120.11 | -68.55 | -145.22 | -75.44 | -- | -- | -2,176.15 | -1,432.10 | -- | -- | 0.1729 | -- | -46.65 | 11.41 | -18.08 | -- | 25.84 | -- |
| Starpharma Holdings Ltd | 10.63m | -8.40m | 55.63m | 50.00 | -- | 1.61 | -- | 5.23 | -0.0205 | -0.0205 | 0.0259 | 0.0837 | 0.2092 | 0.282 | 2.10 | -- | -16.53 | -28.47 | -20.70 | -33.66 | 92.67 | 71.62 | -79.00 | -391.82 | 5.22 | -- | 0.0833 | -- | -14.10 | -3.22 | 3.19 | -- | 11.58 | -- |
Data as of Apr 26 2024. Currency figures normalised to Prescient Therapeutics Ltd's reporting currency: Australian Dollar AUD
0.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 406.50k | 0.05% |
| DFA Australia Ltd.as of 31 Mar 2024 | 57.23k | 0.01% |
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
